erythrocyte glutathione reductase activation coefficient assay Kit The role of glutathione reductase
Description
doi: 10.1371/journal.pone.0058389 250 KimJ-SYangMLeeC-GKimS-DKimJ-KYangK
Radiother Oncol (2008) 88(2):25868
PMID: 31517177
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
doi: 10.3390/cells7100159 42 MorinSSimardMRiouxGJulienPPouliotR
The 6-month PFS was 30.2% and the 1-year OS was 38.1%
